Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration.
Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab.
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.
Sex-related factors in multiple sclerosis susceptibility and progression.
Fatigue, depression and sleep disturbances in Iranian patients with multiple sclerosis.
Pelvic Floor Muscle Training With and Without Electrical Stimulation in the Treatment of Lower Urinary Tract Symptoms in Women With Multiple Sclerosis.
Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection-a case report.
Fingolimod phosphate promotes the neuroprotective effects of microglia.
Tumefactive multiple sclerosis lesions under fingolimod treatment.
Therapeutic Testosterone Administration Preserves Excitatory Synaptic Transmission in the Hippocampus during Autoimmune Demyelinating Disease.
No impact of adult attachment and temperament on clinical variability in patients with clinically isolated syndrome and early multiple sclerosis.
Confounding in association studies: month of birth and multiple sclerosis.
Genetic analysis of the aquaporin-4 gene for anti-AQP4 antibody-positive neuromyelitis optica in a Japanese population.
Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.
First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.
Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).
lipid-specific IgM bands in csf associated with a reduced risk of developing pml during treatment with natalizumab.
Meralgia paresthetica after subcutaneous injection of glatiramer acetate.
An Open Label Extension of the LAQ/5062 and LAQ/5063 Studies to Assess the Long Term Safety and Tolerability of Laquinimod 0.6mg in RRMS Patients
Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients.
Ono to enter license agreements with Merck KGaA
Validation of a Dutch version of the Neurological Fatigue Index (NFI-MS) for patients with multiple sclerosis in the Netherlands.
Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.
Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis.

Pages